Authors
Dilara Demirel, Ebru Güneş Yalçın, Hanife Avcı, Uğur Özçelik, Umay Kavgacı, Tuğçe Kantemir, Ömer Faruk İpek, Nagehan Emiralioğlu Ordukaya, Deniz Doğru
Published in
Turkish archives of pediatrics. Volume 61. Issue 10. Pages 904-910. Jul 20, 2026. Epub Jul 20, 2026.
Abstract
This study aimed to evaluate the frequency, nature, and potential factors associated with adverse events associated with cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy in a pediatric cystic fibrosis (CF) population.
A single-center, retrospective cohort study was conducted at a tertiary care center. Pediatric patients with CF who received CFTR modulator therapy (ivacaftor monotherapy or elexacaftor/tezacaftor/ivacaftor combination) between January 2021 and January 2025 were included. Clinical characteristics and adverse events were analyzed, and patients with and without adverse events were compared.
The study included 100 patients (mean age, 141.5 ± 55.3 months). Adverse events were reported in 24 (24%) patients. Patients experiencing adverse events were significantly older than those who did not (P=.026). The most frequent adverse events were skin rash (33.3%), elevated creatine kinase (20.8%), and gastrointestinal complaints (12.5%). Treatment interruption was required in 12 patients; however, only 1 patient permanently discontinued therapy due to persistent rash and elevated liver enzymes. No severe hepatic or systemic complications occurred.
Cystic fibrosis transmembrane conductance regulator modulators are generally well tolerated in the pediatric population. Most adverse events are mild, transient, and manageable through routine monitoring and temporary cessation, allowing for the safe continuation of therapy.
PMID:
42826236
Bibliographic data and abstract were imported from PubMed on 03 Oct 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 10
- Comments 0